Second, there was a lack of complete data collections regarding functional status (e.g., Karnofsky and ECOG performance status scoring) and gene mutation (e.g., EGFR, KRAS and ALK) that may influence tumor progression. This evidence concerns the gene KRAS and neoplasm.